Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 7 (2010), Issue 2 (February)

1. Therapeutic targeting of chemokine interactions in atherosclerosis.
   Nat Rev Drug Discov, 9(2): 141-53. [Abstract] [Full-text]
2. Single-dose versus single-day antibiotic prophylaxis for orthognathic surgery: a prospective, randomized, double-blind clinical study.
   J Oral Maxillofac Surg, 68(2): 344-6. [Abstract] [Full-text]
3. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
   Lancet, 375(9712): 377-84. [Abstract] [Full-text]
4. Strategies for treating idiopathic pulmonary fibrosis.
   Nat Rev Drug Discov, 9(2): 129-40. [Abstract] [Full-text]
5. Advances in target therapy for lung cancer.
   Jpn J Clin Oncol, 40(2): 101-6. [Abstract] [Full-text]
6. The HIV-1 transgenic rat as a model for HIV-1 infected individuals on HAART.
   J Neuroimmunol, 218(1): 94-101. [Abstract] [Full-text]
7. Suicide associated with corticosteroid use during chemotherapy: case report.
   Jpn J Clin Oncol, 40(2): 174-6. [Abstract] [Full-text]
8. Regulation of the protein-loading capacity of hydroxyapatite by mercaptosuccinic acid modification.
   Acta Biomater, 6(3): 830-5. [Abstract] [Full-text]
9. Porous bioactive diopside (CaMgSi(2)O(6)) ceramic microspheres for drug delivery.
   Acta Biomater, 6(3): 820-9. [Abstract] [Full-text]
10. Synthesis and characterization of thermoresponsive polyamidoamine-polyethylene glycol-poly(D,L-lactide) core-shell nanoparticles.
    Acta Biomater, 6(3): 1131-9. [Abstract] [Full-text]
11. Influence of lactose addition to gentamicin-loaded acrylic bone cement on the kinetics of release of the antibiotic and the cement properties.
    Acta Biomater, 6(3): 804-11. [Abstract] [Full-text]
12. Controlled and extended drug release behavior of chitosan-based nanoparticle carrier.
    Acta Biomater, 6(3): 1140-8. [Abstract] [Full-text]
13. Ultrasound-enhanced drug dispersion through solid tumours and its possible role in aiding ultrasound-targeted cancer chemotherapy.
    Cancer Lett, 288(1): 94-8. [Abstract] [Full-text]
14. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Cancer Lett, 288(2): 251-60. [Abstract] [Full-text]
15. Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death.
    Cancer Lett, 287(2): 216-23. [Abstract] [Full-text]
16. Transglutaminase 2 expression levels regulate sensitivity to cystamine plus TRAIL-mediated apoptosis.
    Cancer Lett, 287(2): 224-30. [Abstract] [Full-text]
17. Spontaneous and 5-fluorouracil-induced centrosome amplification lowers the threshold to resveratrol-evoked apoptosis in colon cancer cells.
    Cancer Lett, 288(1): 36-41. [Abstract] [Full-text]
18. Concurrent chemoradiation with carboplatin-5-fluorouracil versus cisplatin in locally advanced oropharyngeal cancers: is more always better?
    Int J Radiat Oncol Biol Phys, 76(2): 410-6. [Abstract] [Full-text]
19. Physico-chemical characterization of an amphiphilic cyclodextrin/genistein complex.
    J Pharm Biomed Anal, 51(5): 1064-8. [Abstract] [Full-text]
20. Preparation and solid-state characterization of bupivacaine hydrochloride cyclodextrin complexes aimed for buccal delivery.
    J Pharm Biomed Anal, 52(1): 9-18. [Abstract] [Full-text]
21. Influence of pH on transungual passive and iontophoretic transport.
    J Pharm Sci, 99(4): 1955-67. [Abstract] [Full-text]
22. Propagation of uncertainty in nasal spray in vitro performance models using Monte Carlo simulation: part I. Model prediction using Monte Carlo simulation.
    J Pharm Sci, 99(4): 2114-22. [Abstract] [Full-text]
23. Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery.
    J Pharm Sci, 99(4): 2018-31. [Abstract] [Full-text]
24. Effect of irradiation on parathyroid hormone PTH(1-34) coated on a novel transdermal microprojection delivery system to produce a sterile product--adhesive compatibility.
    J Pharm Sci, 99(4): 2123-34. [Abstract] [Full-text]
25. Microchannels created by sugar and metal microneedles: characterization by microscopy, macromolecular flux and other techniques.
    J Pharm Sci, 99(4): 1931-41. [Abstract] [Full-text]
26. Nanoparticle design characterized by in silico preparation parameter prediction using ensemble models.
    J Pharm Sci, 99(4): 1982-96. [Abstract] [Full-text]
27. Intranasal delivery to the central nervous system: mechanisms and experimental considerations.
    J Pharm Sci, 99(4): 1654-73. [Abstract] [Full-text]
28. Development of patch and spray formulations for enhancing topical delivery of sinomenine hydrochloride.
    J Pharm Sci, 99(4): 1790-9. [Abstract] [Full-text]
29. Adenocarcinoma of the paranasal sinuses and nasal cavity with lung metastasis showing complete response to combination chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF): a case report.
    Auris Nasus Larynx, 37(2): 238-43. [Abstract] [Full-text]
30. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Br J Cancer, 102(3): 500-5. [Abstract] [Full-text]
31. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.
    Br J Cancer, 102(3): 475-81. [Abstract] [Full-text]
32. Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.
    Br J Cancer, 102(3): 495-9. [Abstract] [Full-text]
33. A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer.
    Cancer Invest, 28(2): 208-15. [Abstract] [Full-text]
34. Spontaneous intracranial hypotension syndrome: a novel speculative physiopathological hypothesis and a novel patch method in a series of 28 consecutive patients.
    J Neurosurg, 112(2): 300-6. [Abstract] [Full-text]
35. Spontaneous formation of nanosized unilamellar polyion complex vesicles with tunable size and properties.
    J Am Chem Soc, 132(5): 1631-6. [Abstract] [Full-text]
36. Dipolar molecules as impellers achieving electric-field-stimulated release.
    J Am Chem Soc, 132(5): 1450-1. [Abstract] [Full-text]
37. Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis.
    Int J Cancer, 126(7): 1749-60. [Abstract] [Full-text]
38. Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer.
    Int J Cancer, 126(7): 1761-9. [Abstract] [Full-text]
39. Biocompatibility of surfactant-templated polyurea-nanoencapsulated macroporous silica aerogels with plasma platelets and endothelial cells.
    J Biomed Mater Res A, 92(4): 1431-9. [Abstract] [Full-text]
40. Starch-based polymeric carriers for oral-insulin delivery.
    J Biomed Mater Res A, 92(4): 1392-7. [Abstract] [Full-text]
41. Efficacy of poly(sebacic acid-co-ricinoleic acid) biodegradable delivery system for intratumoral delivery of paclitaxel.
    J Biomed Mater Res A, 92(4): 1283-91. [Abstract] [Full-text]
42. Characterization of nitric oxide-releasing microparticles for the mucosal delivery.
    J Biomed Mater Res A, 92(4): 1233-43. [Abstract] [Full-text]
43. Development of new chitosan/carrageenan nanoparticles for drug delivery applications.
    J Biomed Mater Res A, 92(4): 1265-72. [Abstract] [Full-text]
44. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
    Anticancer Drugs, 21(3): 306-12. [Abstract] [Full-text]
45. Chemical delivery system of metaiodobenzylguanidine (MIBG) to the central nervous system.
    J Med Chem, 53(3): 1281-7. [Abstract] [Full-text]
46. Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-kappaB.
    Anticancer Drugs, 21(3): 288-96. [Abstract] [Full-text]
47. Intraoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I study.
    Anticancer Drugs, 21(3): 320-5. [Abstract] [Full-text]
48. Effective antitumor activity of paclitaxel-loaded poly (epsilon-caprolactone)/pluronic F68 nanoparticles after intratumoral delivery into the murine breast cancer model.
    Anticancer Drugs, 21(3): 261-9. [Abstract] [Full-text]
49. Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
    Anticancer Drugs, 21(3): 313-9. [Abstract] [Full-text]
50. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women.
    J Infect Dis, 201(5): 681-90. [Abstract] [Full-text]
51. Menopausal hormone therapy use and risk of invasive colon cancer: the California Teachers Study.
    Am J Epidemiol, 171(4): 415-25. [Abstract] [Full-text]
52. Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement.
    J Clin Endocrinol Metab, 95(2): 567-77. [Abstract] [Full-text]
53. Leptin replacement prevents weight loss-induced metabolic adaptation in congenital leptin-deficient patients.
    J Clin Endocrinol Metab, 95(2): 851-5. [Abstract] [Full-text]
54. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.
    Blood, 115(5): 948-56. [Abstract] [Full-text]
55. Standard care impact on effects of highly active antiretroviral therapy adherence interventions: A meta-analysis of randomized controlled trials.
    Arch Intern Med, 170(3): 240-50. [Abstract] [Full-text]
56. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
    J Clin Oncol, 28(5): 859-65. [Abstract] [Full-text]
57. Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy.
    Cancer, 116(4): 805-13. [Abstract] [Full-text]
58. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer.
    Cancer, 116(4): 791-8. [Abstract] [Full-text]
59. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.
    J Clin Oncol, 28(5): 761-6. [Abstract] [Full-text]
60. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    J Clin Oncol, 28(5): 800-7. [Abstract] [Full-text]
61. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.
    J Clin Oncol, 28(5): 808-14. [Abstract] [Full-text]
62. Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a north central cancer treatment group (NCCTG)/ national surgical adjuvant breast and bowel project (NSABP) phase II intergroup trial, N9945/CI-66.
    J Clin Oncol, 28(5): 853-8. [Abstract] [Full-text]
63. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203).
    J Clin Oncol, 28(5): 753-60. [Abstract] [Full-text]
64. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.
    J Clin Oncol, 28(5): 866-71. [Abstract] [Full-text]
65. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte.
    J Clin Oncol, 28(5): 822-9. [Abstract] [Full-text]
66. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
    J Clin Oncol, 28(5): 723-30. [Abstract] [Full-text]
67. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.
    Gynecol Oncol, 116(3): 323-5. [Abstract] [Full-text]
68. Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology.
    Gynecol Oncol, 116(3): 317-22. [Abstract] [Full-text]
69. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
    Gynecol Oncol, 116(3): 301-6. [Abstract] [Full-text]
70. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Gynecol Oncol, 116(3): 307-11. [Abstract] [Full-text]
71. Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.
    Gynecol Oncol, 116(3): 442-6. [Abstract] [Full-text]
72. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gynecol Oncol, 116(3): 340-4. [Abstract] [Full-text]
73. Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors.
    Gynecol Oncol, 116(3): 438-41. [Abstract] [Full-text]
74. Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial.
    Gynecol Oncol, 116(3): 312-6. [Abstract] [Full-text]
75. Glucose-responsive composite microparticles based on chitosan, concanavalin A and dextran for insulin delivery.
    Colloids Surf B Biointerfaces, 76(2): 483-8. [Abstract] [Full-text]
76. Lipid/particle assemblies based on maltodextrin-gum arabic core as bio-carriers.
    Colloids Surf B Biointerfaces, 76(2): 449-55. [Abstract] [Full-text]
77. Fabrication of cationic nanomicelle from chitosan-graft-polycaprolactone as the carrier of 7-ethyl-10-hydroxy-camptothecin.
    Colloids Surf B Biointerfaces, 76(2): 475-82. [Abstract] [Full-text]
78. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial.
    Ann Intern Med, 152(4): 211-7. [Abstract] [Full-text]
79. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
    Eur J Haematol, 84(3): 223-8. [Abstract] [Full-text]
80. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Eur J Haematol, 84(3): 201-11. [Abstract] [Full-text]
81. The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
    Eur J Haematol, 84(3): 266-70. [Abstract] [Full-text]
82. Pediatric dose selection.
    Clin Pharmacol Ther, 87(3): 270-1. [Abstract] [Full-text]
83. Increasing access to nonprescription medicines: a global public health challenge and opportunity.
    Clin Pharmacol Ther, 87(3): 267-9. [Abstract] [Full-text]
84. A model-based approach to dose selection in early pediatric development.
    Clin Pharmacol Ther, 87(3): 294-302. [Abstract] [Full-text]
85. A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.
    Clin Pharmacol Ther, 87(3): 303-10. [Abstract] [Full-text]
86. Unmasking of PML by HAART: unusual clinical features and the role of IRIS.
    J Neuroimmunol, 219(1): 100-4. [Abstract] [Full-text]
87. Does response to induction chemotherapy predict survival for locally advanced non-small-cell lung cancer? Secondary analysis of RTOG 8804/8808.
    Int J Radiat Oncol Biol Phys, 76(3): 802-8. [Abstract] [Full-text]
88. Induction and concurrent taxanes enhance both the pulmonary metabolic radiation response and the radiation pneumonitis response in patients with esophagus cancer.
    Int J Radiat Oncol Biol Phys, 76(3): 816-23. [Abstract] [Full-text]
89. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.
    Int J Radiat Oncol Biol Phys, 76(3): 824-30. [Abstract] [Full-text]
90. Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial.
    Int J Radiat Oncol Biol Phys, 76(3): 809-15. [Abstract] [Full-text]
91. Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.
    Leuk Res, 34(3): 379-86. [Abstract] [Full-text]
92. Effect of estrogen on bladder nociception in rats.
    J Urol, 183(3): 1201-5. [Abstract] [Full-text]
93. Potentially inappropriate medication use in older adults with mild cognitive impairment.
    J Gerontol A Biol Sci Med Sci, 65(3): 318-21. [Abstract] [Full-text]
94. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis.
    Leuk Res, 34(3): 364-72. [Abstract] [Full-text]
95. Differential tumor-targeting abilities of three single-domain antibody formats.
    Cancer Lett, 289(1): 81-90. [Abstract] [Full-text]
96. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.
    Leuk Res, 34(3): 284-8. [Abstract] [Full-text]
97. The role of myeloablative chemotherapy with autologous hematopoietic cell rescue in central nervous system germ cell tumors.
    Pediatr Blood Cancer, 54(4): 644-6. [Abstract] [Full-text]
98. Non-cerebellar primitive neuroectodermal tumors (PNET): summary of the Milan consensus and state of the art workshop on marrow ablative chemotherapy with hematopoietic cell rescue for malignant brain tumors of childhood and adolescents.
    Pediatr Blood Cancer, 54(4): 638-40. [Abstract] [Full-text]
99. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
    Pediatr Blood Cancer, 54(4): 538-45. [Abstract] [Full-text]
100. Ongoing remission after intensive ALL-type chemotherapy in pediatric intestinal T-cell lymphoma.
     Pediatr Blood Cancer, 54(4): 610-2. [Abstract] [Full-text]
101. Right foot congenital infantile fibrosarcoma treated only with chemotherapy.
     Pediatr Blood Cancer, 54(4): 618-20. [Abstract] [Full-text]
102. Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system.
     Pediatr Blood Cancer, 54(4): 591-5. [Abstract] [Full-text]
103. Central nervous system involvement at the time of presentation in acute promyelocytic leukemia.
     Pediatr Blood Cancer, 54(4): 603-5. [Abstract] [Full-text]
104. Second complete remission of relapsed medulloblastoma induced by metronomic chemotherapy.
     Pediatr Blood Cancer, 54(4): 616-7. [Abstract] [Full-text]
105. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.
     J Infect Dis, 201(5): 672-80. [Abstract] [Full-text]
106. Cell penetrating peptides: overview and applications to the delivery of oligonucleotides.
     Cell Mol Life Sci, 67(5): 715-26. [Abstract] [Full-text]
107. Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats.
     Cancer Chemother Pharmacol, 65(5): 953-9. [Abstract] [Full-text]
108. A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer.
     Cancer Chemother Pharmacol, 65(5): 871-6. [Abstract] [Full-text]
109. A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies.
     Cancer Chemother Pharmacol, 65(5): 863-9. [Abstract] [Full-text]
110. Passive leg raising is predictive of fluid responsiveness in spontaneously breathing patients with severe sepsis or acute pancreatitis.
     Crit Care Med, 38(3): 819-25. [Abstract] [Full-text]
111. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
     J Clin Oncol, 28(6): 942-8. [Abstract] [Full-text]
112. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
     J Clin Oncol, 28(6): 911-7. [Abstract] [Full-text]
113. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
     J Clin Oncol, 28(6): 918-27. [Abstract] [Full-text]
114. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.
     J Clin Oncol, 28(6): 1031-7. [Abstract] [Full-text]
115. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
     J Clin Oncol, 28(6): 955-9. [Abstract] [Full-text]
116. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
     J Clin Oncol, 28(6): 949-54. [Abstract] [Full-text]
117. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.
     J Clin Oncol, 28(6): 1047-53. [Abstract] [Full-text]
118. Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP.
     J Clin Oncol, 28(6): 1017-24. [Abstract] [Full-text]
119. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
     J Clin Oncol, 28(6): 976-83. [Abstract] [Full-text]
120. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients.
     J Clin Oncol, 28(6): 984-90. [Abstract] [Full-text]
121. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
     Mol Pharmacol, 77(3): 483-94. [Abstract] [Full-text]
122. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
     Blood, 115(7): 1343-50. [Abstract] [Full-text]
123. Therapeutic options for postmenopausal female sexual dysfunction.
     Climacteric, 13(2): 103-20. [Abstract] [Full-text]
124. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women.
     Climacteric, 13(2): 147-56. [Abstract] [Full-text]
125. The effects of hormone replacement therapy on myocardial performance in early postmenopausal women.
     Climacteric, 13(2): 157-70. [Abstract] [Full-text]
126. Hormone therapy in Brazilian postmenopausal women with chronic hepatitis C: a pilot study.
     Climacteric, 13(2): 179-86. [Abstract] [Full-text]
127. Homeopathic prescribing for chronic conditions in equine veterinary practice in the UK.
     Vet Rec, 166(8): 234-8. [Abstract] [Full-text]
128. Incidence and risk factors of persistent air leak after major pulmonary resection and use of chemical pleurodesis.
     Ann Thorac Surg, 89(3): 891-7; discussion 897-8. [Abstract] [Full-text]
129. Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy.
     Am J Ophthalmol, 149(3): 441-6.e1-2. [Abstract] [Full-text]
130. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.
     Lancet, 375(9715): 641-8. [Abstract] [Full-text]
131. Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation.
     Am J Ophthalmol, 149(3): 472-81.e1. [Abstract] [Full-text]
132. Drug interactions evaluation: an integrated part of risk assessment of therapeutics.
     Toxicol Appl Pharmacol, 243(2): 134-45. [Abstract] [Full-text]
133. One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
     Am J Ophthalmol, 149(3): 465-71.e1. [Abstract] [Full-text]
134. Diffuse large B-cell lymphoma presenting as piriformis syndrome.
     Muscle Nerve, 41(3): 419-22. [Abstract] [Full-text]
135. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.
     AJR Am J Roentgenol, 194(3): 830-7. [Abstract] [Full-text]
136. Combination therapy in multiple sclerosis.
     Lancet Neurol, 9(3): 299-308. [Abstract] [Full-text]
137. Disability pension as predictor of later use of benzodiazepines among benzodiazepine users.
     Soc Sci Med, 70(6): 921-5. [Abstract] [Full-text]
138. Transient estradiol exposure during middle age in ovariectomized rats exerts lasting effects on cognitive function and the hippocampus.
     Endocrinology, 151(3): 1194-203. [Abstract] [Full-text]
139. First report of a medullar cord compression secondary to osseous plasmacytoma successfully treated with bortezomib and dexamethasone.
     Leuk Res, 34(4): e97-9. [Abstract] [Full-text]
140. High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia.
     Leuk Res, 34(4): 545-7. [Abstract] [Full-text]
141. Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia.
     Leuk Res, 34(4): 487-91. [Abstract] [Full-text]
142. Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells.
     Leuk Res, 34(4): 535-41. [Abstract] [Full-text]
143. Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.
     Leuk Res, 34(4): 454-7. [Abstract] [Full-text]
144. Prevalence of depression diagnosis and prescription of antidepressants in East and West Germany: an analysis of health insurance data.
     Soc Psychiatry Psychiatr Epidemiol, 45(3): 329-35. [Abstract] [Full-text]
145. Clindamycin-resistant group B Streptococcus and failure of intrapartum prophylaxis to prevent early-onset disease.
     J Pediatr, 156(3): 501-3. [Abstract] [Full-text]
146. Decrease in wound tensile strength following post-surgical estrogen replacement therapy in ovariectomized rats during the early phase of healing is mediated via ER-alpha rather than ER-beta: a preliminary report.
     J Surg Res, 159(1): e25-8. [Abstract] [Full-text]
147. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial.
     JAMA, 303(8): 739-46. [Abstract] [Full-text]
148. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
     J Clin Oncol, 28(7): 1124-30. [Abstract] [Full-text]
149. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.
     J Clin Oncol, 28(7): 1138-44. [Abstract] [Full-text]
150. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.
     J Clin Oncol, 28(7): 1181-9. [Abstract] [Full-text]
151. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
     J Clin Oncol, 28(7): 1215-23. [Abstract] [Full-text]
152. Physician order entry or nurse order entry? Comparison of two implementation strategies for a computerized order entry system aimed at reducing dosing medication errors.
     J Med Internet Res, 12(1): e5. [Abstract] [Full-text]
153. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma.
     Cancer, 116(5): 1315-25. [Abstract] [Full-text]
154. Implications of key trials in advanced nonsmall cell lung cancer.
     Cancer, 116(5): 1155-64. [Abstract] [Full-text]
155. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.
     Cancer, 116(5): 1243-51. [Abstract] [Full-text]
156. Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
     J Surg Oncol, 101(3): 222-7. [Abstract] [Full-text]
157. Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer.
     Cancer, 116(5): 1344-9. [Abstract] [Full-text]
158. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
     Cancer, 116(5): 1210-7. [Abstract] [Full-text]
159. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).
     Blood, 115(8): 1530-3. [Abstract] [Full-text]
160. Ecological effects of selective decontamination on resistant gram-negative bacterial colonization.
     Am J Respir Crit Care Med, 181(5): 452-7. [Abstract] [Full-text]
161. Early profiles of clinical evolution after intravenous thrombolysis in an unselected stroke population.
     J Neurol Neurosurg Psychiatry, 81(3): 282-5. [Abstract] [Full-text]
162. Targeting the 90 kDa heat shock protein improves photodynamic therapy.
     Cancer Lett, 289(2): 188-94. [Abstract] [Full-text]
163. Sunlight, hormone replacement status and colorectal cancer risk in postmenopausal women.
     Int J Cancer, 126(8): 1997-2001. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.